Almotriptan
Therapeutic indications
Almotriptan is indicated for:
Migraine attacks
Irrespective of gender only Adults (18 years old or older)
Almotriptan is indicated for the acute treatment of the headache phase of migraine attacks with or without aura.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 12.5-25 mg
Contraindications
Active ingredient Almotriptan is contraindicated in the following cases:
Severe hepatic disease
No gender/age discrimination
Treatment with almotriptan is contraindicated in patients with severe hepatic disease.
Ergotamine, ergotamine derivatives, 5-HT1B/1D agonists
No gender/age discrimination
Concomitant administration of almotriptan with ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/1D agonists is contraindicated.
Ischaemic heart disease, hypertension
No gender/age discrimination
Almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal’s angina) or severe hypertension and uncontrolled mild or moderate hypertension.
Lactation
No gender/age discrimination
There are no data regarding excretion of almotriptan in human milk. Studies in rats have shown that almotriptan and/or its metabolites are excreted in milk.
Caution should therefore be exercised when prescribing during lactation. Infant exposure may be minimised by avoiding breast feeding for 24 hours after treatment.
Cerebrovascular accident (CVA) or transient ischaemic attack (TIA), peripheral vascular disease
No gender/age discrimination
Almotriptan should not be used in patients with a previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA). Peripheral vascular disease.